Offerings - Offering: 1	Feb. 27, 2025 USD ($) shares
Offering:
Fee Previously Paid	false
Other Rule	true
Security Type	Equity
Security Class Title	Ordinary Shares, no par value
Amount Registered \| shares	2,085,261
Proposed Maximum Offering Price per Unit	20.97
Maximum Aggregate Offering Price	$ 43,727,923.17
Fee Rate	0.01531%
Amount of Registration Fee	$ 6,694.75
Offering Note	(1) This Registration Statement covers 1,001,424 ordinary shares of NovoCure Limited (the “Registrant”) available for issuance pursuant to awards under the NovoCure Limited 2024 Omnibus Incentive Plan (the “2024 Plan”) and an additional 1,083,837 ordinary shares of the Registrant available for issuance pursuant to awards under the NovoCure Limited Employee Share Purchase Plan (“ESPP”). (2) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers any additional securities of the Registrant that become issuable under the Plan relating to adjustments for changes resulting from a stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration. (3) Completed pursuant to Rule 457(c) and Rule 457(h) of the Securities Act, based on the average of the high and low prices reported for the Registrant’s ordinary shares on the NASDAQ Global Select Market on February 25, 2025.

Offerings - Offering: 1

Feb. 27, 2025

USD ($)

Offering:

false

true

Equity

Ordinary Shares, no par value

Amount Registered | shares

2,085,261

Proposed Maximum Offering Price per Unit

20.97

Maximum Aggregate Offering Price

$ 43,727,923.17

Fee Rate

0.01531%

Amount of Registration Fee

$ 6,694.75

Offering Note

(1) This Registration Statement covers 1,001,424 ordinary shares of NovoCure Limited (the “Registrant”) available for issuance pursuant to awards under the NovoCure Limited 2024 Omnibus Incentive Plan (the “2024 Plan”) and an additional 1,083,837 ordinary shares of the Registrant available for issuance pursuant to awards under the NovoCure Limited Employee Share Purchase Plan (“ESPP”).

(2) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers any additional securities of the Registrant that become issuable under the Plan relating to adjustments for changes resulting from a stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration.

(3) Completed pursuant to Rule 457(c) and Rule 457(h) of the Securities Act, based on the average of the high and low prices reported for the Registrant’s ordinary shares on the NASDAQ Global Select Market on February 25, 2025.